MYGN - Myriad Genetics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
28.69
+0.28 (+0.99%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close28.41
Open28.50
Bid28.70 x 800
Ask28.70 x 2200
Day's Range27.80 - 28.94
52 Week Range20.10 - 48.40
Volume591,663
Avg. Volume1,047,212
Market Cap2.134B
Beta (5Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging
    Zacks

    Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging

    The result of this clinical trial is a major stride forward in Myriad Genetics' (MYGN) commitment toward strengthening its portfolio of depressive disorder treatments.

  • Myriad Genetics' Cancer Companion Diagnostic Test Gets FDA Nod
    Zacks

    Myriad Genetics' Cancer Companion Diagnostic Test Gets FDA Nod

    Myriad Genetics (MYGN) expands the use of BRACAnalysis CDx as a companion diagnostic test for metastatic pancreatic cancer with the receipt of the FDA clearance.

  • This Genetic-Testing Stock Popped, Then Slipped, On Its FDA Approval
    Investor's Business Daily

    This Genetic-Testing Stock Popped, Then Slipped, On Its FDA Approval

    Shares of Myriad Genetics initially popped Monday after the Food and Drug Administration approved the company's genetic test, dubbed BRACAnalysis CDx, for pancreatic cancer patients.

  • Barrons.com

    Nio Stock Is Soaring, Myriad Genetics Jumps, as the Dow Holds Its Ground

    Wall Street is set for a sleepy open Monday with stock futures indicating modest gains across all three indexes. The Dow Jones Industrial Average, S&P 500 and Nasdaq Compositewere all set to open up 0.1% as of 8:20 a.m. in what is expected to be a quiet day for trading. (AZN) (ticker: AZN) and (MRK) (MRK) were up 0.6% and 0.2%, respectively, after Lynparza, the ovarian-cancer drug they market, won approval by the Food and Drug Administration to be used to treat advanced pancreatic cancer.

  • MarketWatch

    Myriad Genetics's stock surges after FDA approval of diagnostic test for pancreatic cancer

    Share of Myriad Genetics Inc. shot up 8.3% in premarket trading Monday, after the molecular diagnostics company said its BRACAnalysis CDx was approved by the Food and Drug Administration as a companion test to identify patients with metastatic pancreatic cancer, who are candidates for treatment with Lynparza. BRACAnalysis CDx is the only FDA-approved genetic test for this indication. Lynparza is marketed by AstraZeneca PLC and Merck & Co. Inc. . "The approval of the BRACAnalysis CDx test for patients with pancreatic cancer highlights our shared vision and long-standing collaboration with Myriad to advance precision medicine for patients in need of new treatments," said Ruth March, head of precision medicine at AstraZeneca. Myriad Genetics's stock has lost 7.9% year to date through Friday, while the S&P 500 has gained 29%.

  • TheStreet.com

    Myriad Genetics Spikes on FDA Approval of Pancreatic Cancer Diagnostic Test

    The Food and Drug Administration approves BRACAnalysis CDx, Myriad Genetics' metastatic pancreatic cancer diagnostic tool for patients who are eligible for treatment with Lynparaza, a drug marketed by AstraZeneca.

  • Does Myriad Genetics's (NASDAQ:MYGN) Share Price Gain of 47% Match Its Business Performance?
    Simply Wall St.

    Does Myriad Genetics's (NASDAQ:MYGN) Share Price Gain of 47% Match Its Business Performance?

    It hasn't been the best quarter for Myriad Genetics, Inc. (NASDAQ:MYGN) shareholders, since the share price has fallen...

  • Barrons.com

    Myriad Genetics Is Tumbling After The Wall Street Journal Highlighted the Risks of Acting on Genetic Testing

    Over the weekend, Myriad was the subject of a Wall Street Journal report that profiled a woman who had her ovaries and fallopian tubes removed after a genetic test showed a heightened risk of cancer. Years later, the woman learned that an updated interpretation of the lab results showed that the specific mutation may not be linked to an increase in cancer risk.

  • Hedge Funds Are Dumping Myriad Genetics, Inc. (MYGN)
    Insider Monkey

    Hedge Funds Are Dumping Myriad Genetics, Inc. (MYGN)

    Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018 as investors first worried over the possible ramifications of rising interest rates and the escalation of the trade war with China. The hedge funds and institutional investors we track […]

  • Myriad Genetics Presents Trial Outcomes in Breast Health
    Zacks

    Myriad Genetics Presents Trial Outcomes in Breast Health

    Myriad Genetics' (MYGN) PRS enhances the detection of breast cancer risk in women having PV in high- and moderate-penetrance breast cancer genes.

  • Hedge Funds Love Tri Pointe Group Inc (TPH) Way More Than These 3 Stocks
    Insider Monkey

    Hedge Funds Love Tri Pointe Group Inc (TPH) Way More Than These 3 Stocks

    Is Tri Pointe Group Inc (NYSE:TPH) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market […]

  • Myriad Genetics Reports Favorable Study Result on Prequel
    Zacks

    Myriad Genetics Reports Favorable Study Result on Prequel

    Myriad Genetics (MYGN) posts breakthrough results on Prequel Prenatal Screen methodology, proving its superiority over traditional methods.

  • Myriad (MYGN) Up 18.4% Since Last Earnings Report: Can It Continue?
    Zacks

    Myriad (MYGN) Up 18.4% Since Last Earnings Report: Can It Continue?

    Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • MarketWatch

    Myriad shares fall despite positive results on prenatal test

    Shares of Myriad Genetics dropped 3% in premarket trading after the diagnostics maker said its Prequel prenatal screening test is better than non-DNA tests at identifying chromosomal abnormalities in pregnant women with a high body mass index. The study's results were published in the journal Prenatal Diagnosis. Myriad said that Prequel, which uses whole-genome sequencing, can help reduce the need for expensive procedures like amniocentesis or chorionic villus sampling. Sales of its prenatal business, which makes up about 12% of total revenues, rose 5% to $23.5 million in the most recent quarter, up from $18.1 million in the same period a year ago. Myriad's stock has tumbled 14% year-to-date. The S&P 500 is up 24%.

  • Myriad's BRACAnalysis Wins HBOC Risk Assessment Nod in Japan
    Zacks

    Myriad's BRACAnalysis Wins HBOC Risk Assessment Nod in Japan

    The latest approval of Myriad Genetics' (MYGN) BRACAnalysis for HBOC risk assessment in Japan will further validate the superior standard of the BRACAnalysis Diagnostic System, globally.

  • DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
    PR Newswire

    DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm

    Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Utah on behalf of investors that purchased Myriad Genetics, Inc. (NASDAQ: MYGN) securities between September 2, 2016 to August 13, 2019 (the "Class Period"). Investors have until November 26, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

  • Myriad Genetics' Test Added in Disease Activity Measure List
    Zacks

    Myriad Genetics' Test Added in Disease Activity Measure List

    Myriad Genetics' (MYGN) Vectra test receives recognition, with the inclusion in the list of recommended disease activity measures for RA patients.

  • Myriad Genetics Presents New Test Data in Autoimmune Segment
    Zacks

    Myriad Genetics Presents New Test Data in Autoimmune Segment

    Myriad Genetics (MYGN) presents key findings related to Vectra test from its autoimmune segment.

  • Independent Chairman John Henderson Just Bought Shares In Myriad Genetics, Inc. (NASDAQ:MYGN)
    Simply Wall St.

    Independent Chairman John Henderson Just Bought Shares In Myriad Genetics, Inc. (NASDAQ:MYGN)

    Investors who take an interest in Myriad Genetics, Inc. (NASDAQ:MYGN) should definitely note that the Independent...

  • Thomson Reuters StreetEvents

    Edited Transcript of MYGN earnings conference call or presentation 4-Nov-19 9:30pm GMT

    Q1 2020 Myriad Genetics Inc Earnings Call

  • Company News For Nov 6, 2019
    Zacks

    Company News For Nov 6, 2019

    Companies In The News Are: CPE, EVER, MYGN, AAN

  • This Genetic-Testing Stock Plummeted 40% On A Massive Earnings Miss
    Investor's Business Daily

    This Genetic-Testing Stock Plummeted 40% On A Massive Earnings Miss

    Shares of Myriad Genetics crashed Tuesday after the genetic-testing company missed fiscal first-quarter estimates and slashed its full-year outlook. It blamed an administrative change.

  • Myriad Genetics (MYGN) Lags Q1 Earnings and Revenue Estimates
    Zacks

    Myriad Genetics (MYGN) Lags Q1 Earnings and Revenue Estimates

    Myriad Genetics (MYGN) observes a decline in Hereditary Cancer, GeneSight, Vectra as well as Other testing revenues in Q1.

  • MarketWatch

    Myriad Genetics stock plunges to lead premarket losers after earnings miss by wide margin

    Shares of Myriad Genetics Inc. plummeted 35% to pace all premarket decliners, after the molecular diagnostics company reported fiscal first-quarter results that were well below expectations and slashed its full-year outlook. The company reported late Monday a net loss for the quarter to Sept. 30 of $20.6 million, or 28 cents a share, after a loss of $700,000, or 1 cent a share, in the year-ago period. Excluding non-recurring items, such as stock-based compensation expenses and acquisition-related charges, adjusted earnings per share came to 8 cents, below the FactSet consensus of 31 cents. Revenue fell 7.9% to $186.3 million, missing the FactSet consensus of $202.3 million. "We had a challenging start to fiscal year 2020 as hereditary cancer revenue accrual from small payers was impacted by the deletion of the historical hereditary cancer CPT codes," said Chief Executive Mark Capone. The company cut its fiscal 2020 guidance ranges for adjusted EPS to $1.00 to $1.10 from $1.80 to $1.90 and for revenue to $800 million to $810 million from $865 million to $875 million. The stock had gained 21% year to date through Monday, while the S&P 500 has advanced 23%.

  • Barrons.com

    Uber Stock, Shake Shack Are Falling as the Dow Chugs Ahead Again

    STOCKSTOWATCHTODAY BLOG U.S. stock futures were higher Tuesday morning. And third-quarter earnings reports had several companies’ shares moving in premarket trading. Dow Jones Industrial Average futures were up 0.